1. ¹Division of Urology, Maimonides Medical Center and Columbia University, New York, NY, USA
2. ²University of Tennessee Graduate School of Medicine, Knoxville, TN, USA
3. ³New England Research Institute, Watertown, MA, USA
4. ⁴Santa Clara Valley Medical Center, San Jose, CA, USA
5. ⁵Eli Lilly and Company, Indianapolis, IN, USA

Correspondence: Dr R Shabsigh, Division of Urology, Maimonides Medical Center, 904 49th Street, Brooklyn, NY 11219, USA. E-mail: rshabsigh@maimonidesmed.org

Received 2 June 2008; Revised 15 July 2008; Accepted 15 July 2008; Published online 11 September 2008.

Abstract

The purpose of this post hoc analysis was to evaluate response to tadalafil in patients with erectile dysfunction (ED) who reported failures in all sexual intercourse attempts before treatment. In a multicenter, open-label study, 1911 men received tadalafil 20 mg dosed as needed (up to once daily), for 12 weeks following a 4-week treatment-free run-in period. Efficacy measures included the sexual encounter profile (SEP) and the erectile function (EF) domain of the International Index of Erectile Function (IIEF-EF). Approximately, one-half (n=952, 49.9%) of the patients reported no successful intercourse attempts during the 4-week run-in period. Of these, 771 patients (81.0%) had at least one successful intercourse attempt during the treatment period. Furthermore, among responders, mean IIEF-EF scores at study end were similar regardless of success or no success at baseline. Patients who are unable to have successful intercourse should be encouraged to try oral phosphodiesterase type 5 inhibitor treatment for ED.